• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Dermatology

Initial primary invasive or in situ melanoma increases risk of subsequent invasive melanoma

byAdam WhittingtonandAngela Wang
March 23, 2014
in Dermatology, Oncology
Reading Time: 3 mins read
Patients with late stage melanoma remain at risk for further primary melanoma
Share on FacebookShare on Twitter

Image: PD 

1. Development of subsequent primary invasive melanoma following a first invasive or in situ lesion was significantly increased when compared to the age- and sex-matched general population. 

2. Relative risk of subsequent primary invasive melanoma (SPIM) was greatest at the body site of the original invasive lesion, particularly the head. 

Evidence Rating Level: 2 (Good) 

Study Rundown: The increased risk of SPIM has been correlated to both previous diagnosis of initial primary in situ melanoma and to body region of initial invasive melanoma.  However, relative risks by body site have not been previously identified.  Therefore, these authors examined whether body region, sex, age group, and time since diagnosis influenced the likelihood of a SPIM.  The body site of first primary invasive melanoma had no significance on overall relative risk of SPIM, but an initial in situ melanoma on all body regions except the head correlated with higher relative risk of developing SPIM.  The body site with the greatest risk of SPIM was the region of the original invasive lesion for all subgroups.  Additionally, females with a first primary invasive melanoma on the head were more likely to acquire a SPIM compared to males, and the highest risk of developing SPIM in both sexes was within the first year of initial diagnosis.  Strengths of this study include its large population size and participant diversity within the Queensland area.  However, the replacement of a control population by standardized incident ratio calculations may be considered a weakness.

Click to read the study in JAMA Dermatology

RELATED REPORTS

Artificial intelligence matches dermatologists in melanoma diagnosis

2MM: AI Roundup –Dermatology accuracy, faster drug discovery, heart disease detection, and global medical training [September 11th,  2025]

The Scan by 2 Minute Medicine®: Fall boosters, mosquitoes, skin awareness, and Hollywood healing

Relevant Reading: Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin

In-Depth [retrospective cohort]: This study reviewed 39,668 eligible cases of first primary invasive melanoma and 22,845 cases of first primary in situ melanoma between 1982 and 2005 in Queensland, Australia.  Among those, a total of 5,358 patients were diagnosed with SPIM and included in the study cohort.  Standardized incidence ratios (SIRs) were used to measure relative risk and the significance of differences between SIRs was calculated using negative binomial regression.  Results indicated that development of SPIM was 5.4 times more likely (SIR, 5.42; 95% CI, 5.23-5.61) in people with first primary invasive melanoma and 4.6 times more likely (SIR, 4.59; 95% CI, 4.37-4.82) for those with a first in situ primary melanoma than the general population.  For all subgroups, SPIM development was most significant at the site of the original invasive or in situ melanoma, particularly for females with first primary invasive melanoma on the head (SIR, 13.32; 95% CI, 10.28-16.98).  Overall, though, the body region of the first primary invasive melanoma had no effect on the relative risk of SPIM development in the study cohort (P =0.27).

More from this author: Video-based behavioral intervention benefits clinical skin examinations, Biofilm-producing staphylococci occlude eccrine sweat ducts in atopic dermatitis 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: melanoma
Previous Post

Cesarean in the second stage associated with endometritis

Next Post

Child activity levels correlate with mothers’ activity levels

RelatedReports

Patient Basics: Melanoma
AI Roundup

Artificial intelligence matches dermatologists in melanoma diagnosis

September 15, 2025
2 Minute Medicine AI Roundup editorial illustration
AI Roundup

2MM: AI Roundup –Dermatology accuracy, faster drug discovery, heart disease detection, and global medical training [September 11th,  2025]

September 25, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Fall boosters, mosquitoes, skin awareness, and Hollywood healing

August 28, 2025
Significant reduction in prostate screening rates after revised guidelines
Chronic Disease

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

April 28, 2025
Next Post
ADHD stimulant treatment associated with changes in BMI trajectory

Child activity levels correlate with mothers’ activity levels

Avoidable hospitalizations for ESRD increase after transfer to adult care

Low circulating cholesterol in neonates linked with pyloric stenosis

2 Minute Medicine Rewind March 18-24, 2014

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Alcohol use declines but remains above pre-pandemic levels
  • High maternal egg-peanut intake not associated with reduced infant allergy
  • The rotavirus vaccine (ROTASIIL) may reduce the incidence of hospitalization for rotavirus gastroenteritis in children
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.